Gilead Science vies for purchase of Pharmasset

Biotechnology firm Gilead Sciences, the leading maker of HIV drugs, has announced its plans to acquire a rival firm, Pharmasset, for $11 billion....

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

Try FTCWatch FREE for 45 days

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch

Current Issue: 1045
Next Issue: Mar 28, 2023

Browse Archives

In this Issue:

LabMD litigation against FTC lingers
Calendar
Women fraud investigators say gender matters
Taking stock of President Carter’s robust antitrust record
Neil Averitt commentary: The pushback on convenience, resort and junk fees
‘Significant strain’ prevents FTC’s electric industry study
DOJ nabs more guilty pleas in New York bid-rigging scheme
Privacy Corner: Schick speaks on AI’s evolution, the risks and rewards
Bill targeting smart appliances with cameras passes House
Amid new details of Twitter privacy probe, FTC again in partisan cauldron
On the Shelf: Analyzing the growing clout of consultants
Khan says FTC complies with West Virginia v. EPA ruling
People
Calendar
Bedoya flags executive noncompete harms to competitive conditions, franchisee woes
Wilson exit will heighten GOP scrutiny of FTC
Senators seek investigation of CoStar
ABA report on diverse consumers addresses merger analysis
FTC creates new technology office
People

RSS Feed